Explore the future of ocular research with Newcells’ Retinal Organoids eBook. Learn how these cutting-edge models are revolutionizing studies into eye diseases, advancing drug discovery, and paving the way for personalized medicine breakthroughs.
Whether you are investigating disease mechanisms, evaluating drug efficacy, or pioneering therapeutic innovations, this guide equips you with the latest knowledge and protocols to enhance your research. Gain practical insights and discover how retinal organoids are transforming preclinical studies with more accurate, human-relevant models.
Download the guide today and take your retinal research to the next level.
Download the full eBook
About Newcells Biotech
Newcells Biotech develops in vitro cell-based assays for drug and chemical discovery and development.
Using our expertise in induced pluripotent stem cells (iPSCs), cellular physiology, and organoid technology, we build models that incorporate the “best biology” for predicting in vivo behavior of new drugs.
Our experts have developed and launched assays to measure transporter function, safety, and efficacy in a range of cell and tissue types, including kidney, retina and lungs.
We have the capability to develop and implement protocols to measure cilia beat frequency and toxicity on small airway epithelial cells model, retinal toxicity and disease modelling on retinal organoids and retina epithelium, as well as drug transport in the kidney, DDI and nephrotoxicity across human and a range of preclinical species.
Our development teams are creating models of the lung and liver to expand our offer to support early drug discovery and development.
Sponsored Content Policy: News-Medical.net publishes articles and related content that may be derived from sources where we have existing commercial relationships, provided such content adds value to the core editorial ethos of News-Medical.Net which is to educate and inform site visitors interested in medical research, science, medical devices and treatments.